Navigating the analytical verification of growth hormone-releasing hormone (GHRH) analogs requires rigorous documentation and transparent testing methodologies. This guide details the critical analytical benchmarks included in a comprehensive CJC-1295 DAC COA, highlighting the essential chemical differences between modified GHRH variants and establishing quality protocols for laboratory research.
Navigating the analytical verification of growth hormone-releasing hormone (GHRH) analogs requires rigorous documentation and transparent testing methodologies. This guide details the critical analytical benchmarks included in a comprehensive CJC-1295 DAC COA, highlighting the essential chemical differences between modified GHRH variants and establishing quality protocols for laboratory research.
A CJC-1295 DAC COA (Certificate of Analysis) is an essential, lot-specific analytical document verifying the identity, purity, and safety profile of synthesized CJC-1295 with Drug Affinity Complex. It provides independent laboratory proof via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) confirming ≥98% purity, Electrospray Ionization Mass Spectrometry (ESI-MS) confirming exact molecular mass (3647.28 g/mol), and Kinetic Chromogenic LAL assays confirming bacterial endotoxin levels remain under strict threshold limits (<0.1 EU/mg).
For principal investigators evaluating growth hormone-releasing hormone analogs, a verified Certificate of Analysis guarantees that the peptide batch is free from synthesis truncations, heavy metals, TFA salts, and microbial contamination that could otherwise compromise experimental reproducibility in cell culture or animal models.
To maintain rigorous research standards across in vitro and preclinical trials, research compounds must be evaluated against strict quality parameters. PX1 Research subjects every batch of synthetic peptides to independent ISO 17025 accredited laboratory testing before release.
The table below outlines the requisite analytical criteria for CJC-1295 variants, establishing the baseline verification necessary for publication-grade research:
A primary source of confusion in peptide procurement arises from the nomenclature surrounding GHRH analogs. Researchers looking for a cjc-1295 dac coa or a cjc-1295 no dac coa must distinguish between two distinct chemical entities with markedly different pharmacokinetics and structural formulations.
CJC-1295 with DAC incorporates a Drug Affinity Complex—a maleimidopropionic acid linker covalently attached to the C-terminal lysine residue of the 29-amino-acid peptide sequence. In preclinical rodent and non-human primate models, this DAC moiety allows the compound to bioconjugate dynamically to endogenous circulating albumin via a stable thioether bond. This bioconjugation protects the peptide from rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV), extending the biological half-life from approximately 30 minutes to over 6 to 8 days.
Conversely, CJC-1295 No DAC (chemically designated as Modified GRF 1-29) lacks this reactive linker. While it shares the same four substituted amino acids (D-Ala2, Gln8, Ala15, Leu27) that grant initial DPP-IV resistance compared to native GHRH, it does not bind to albumin. Consequently, a cjc-1295 no dac coa reflects a shorter half-life profile (~30 minutes) and a lower overall molecular weight (3367.97 g/mol compared to 3647.28 g/mol for the DAC conjugate). Verification via ESI-MS is essential to confirm that the correct chemical species has been synthesized and supplied.
An authoritative cjc-1295 coa must report complete analytical data rather than summary statements or passing grades. Investigators reviewing documentation from PX1 Research should verify three core testing methodologies on every certificate:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): RP-HPLC separates the primary peptide from synthesis impurities, truncated sequences, and deamidation products. The resulting chromatogram displays peak area percentages. A legitimate cjc-1295-coa must demonstrate a single primary peak accounting for ≥98.0% of the total integrated area at UV detection wavelengths of 214 nm or 220 nm.
2. Electrospray Ionization Mass Spectrometry (ESI-MS): Mass spectrometry verifies molecular identity by measuring the mass-to-charge ratio (m/z) of the ionized compound. For CJC-1295 with DAC, the spectra must confirm a monoisotopic mass corresponding to C165H269N47O46 ( theoretical average mass: 3647.28 Da). For CJC-1295 No DAC, the spectrum must confirm 3367.97 Da. Discrepancies in mass peaks indicate incorrect sequence assembly or incomplete protection group removal during solid-phase peptide synthesis (SPPS).
3. Endotoxin Testing (LAL Assay): Bacterial endotoxins (lipopolysaccharides) derived from Gram-negative bacterial cell walls can trigger profound inflammatory cascades in cellular assays and animal tissue models, skewing research findings. Quantitative Limulus Amebocyte Lysate (LAL) testing measures endotoxin concentrations, which must register below 0.1 EU/mg to ensure suitability for delicate preclinical applications.
When sourcing reagents, searching for a verified cjc-1295 coa usa provider ensures compliance with domestic quality assurance protocols. USA-manufactured peptides produced in GMP-compliant facilities undergo strict quality controls at every step of synthesis, cleavage, purification, and lyophilization.
Imported or unverified peptides frequently lack comprehensive lot traceability, leaving researchers vulnerable to batch-to-batch variation, residual heavy metal contamination (such as lead or arsenic from crude synthesis reagents), and unreacted trifluoroacetic acid (TFA) counter-ion toxicity. Requesting a cjc-1295 coa usa verified document guarantees that testing was performed by an independent, ISO 17025 accredited laboratory using standardized calibration references. Research entities requiring scalable supply can establish standardized procurement parameters through dedicated wholesale peptide accounts.
CJC-1295 functions as a synthetic analog of growth hormone-releasing hormone (GHRH), selectively binding to and activating the GHRH receptor on somatotroph cells in the anterior pituitary gland. In vitro receptor binding assays demonstrate high affinity for the human GHRH receptor, initiating intracellular signaling via the cyclic adenosine monophosphate (cAMP) protein kinase A (PKA) pathway.
Preclinical studies suggest that stimulation of this cascade induces the transcription and pulsatile secretion of endogenous growth hormone (GH). In animal models, the sustained elevation of circulating GH acts on hepatic tissues to stimulate downstream insulin-like growth factor 1 (IGF-1) synthesis. Because IGF-1 regulates cellular proliferation, protein synthesis, nitrogen retention, and extracellular matrix remodeling, GHRH analogs remain primary subjects of study in tissue repair research, metabolic modulation, and age-related physiological decline models.
To fully evaluate growth hormone secretagogues in laboratory models, investigators often compare GHRH analogs against growth hormone secretagogue receptor (GHSR-1a) agonists. While GHRH analogs like CJC-1295 with DAC and CJC-1295 No DAC act specifically at the GHRH receptor, ghrelin mimetics target a distinct pathway. For instance, Ipamorelin selectively binds to GHSR-1a without inducing significant cortisol or prolactin release, whereas GHRP-2 exhibits potent GH release accompanied by minor elevations in ACTH and cortisol in animal models.
Additionally, shorter GHRH fragments like Sermorelin (GRF 1-29) share the initial 29-amino-acid structure of native GHRH but lack the amino acid substitutions present in CJC-1295 that confer enzymatic stability against DPP-IV. Combining a GHRH agonist with a GHSR-1a agonist in preclinical research frequently demonstrates a synergistic elevation of GH release compared to either compound evaluated in isolation. Researchers interested in broader receptor cross-talk can reference our comprehensive guide on GHRH research peptides.
Maintaining peptide integrity after receiving a verified lot requires strict adherence to physical handling guidelines. Synthetic peptides are delivered as lyophilized (freeze-dried) cakes or powders under vacuum, designed to maximize long-term stability.
Reconstitution should be performed using sterile laboratory solvents, typically bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline, depending on assay requirements. The solvent should be directed down the glass vial wall rather than directly onto the lyophilized cake to prevent mechanical shear stress from degrading the peptide chain. Gently swirl the vial until completely dissolved; vortexing must be avoided.
Once reconstituted, aqueous peptide solutions are subject to hydrolytic degradation and oxidation. Aliquot the solution into sterile polypropylene vials to prevent repeated freeze-thaw cycles. Reconstituted CJC-1295 should be stored at 2°C to 8°C for short-term experimentation (up to 30 days) or frozen at -20°C to -80°C for extended stability. Lyophilized vials stored at -20°C remain stable for up to 24 months, provided exposure to ambient moisture is minimized.
High-purity reagents require transparent logistical support to maintain chain-of-custody and degradation prevention. PX1 Research operates climate-controlled distribution centers in California and Arizona, ensuring fast delivery across North America. All orders placed Monday through Friday ship same-day.
Every vial dispatched includes full lot tracking cross-referenced to its published analytical documentation in our online research library. By providing verified HPLC chromatograms, mass spectra, and endotoxin reports, PX1 Research provides academic, biotechnology, and institutional laboratories with the absolute standard in peptide quality assurance.
What information is included in a cjc-1295 dac coa?
A comprehensive cjc-1295 dac coa includes batch lot numbers, manufacturing date, theoretical versus measured molecular weight derived from Mass Spectrometry (ESI-MS), purity percentages determined by RP-HPLC, residual solvent analysis, appearance, and quantitative bacterial endotoxin levels measured via LAL testing.
Where can I view a cjc-1295 coa before purchasing for my laboratory?
PX1 Research provides publicly accessible, lot-specific Certificates of Analysis directly on product pages and within our centralized research library. You can review HPLC chromatograms and ESI-MS reports for every active batch prior to placing an order.
How does a cjc-1295 no dac coa differ from a CJC-1295 with DAC report?
A cjc-1295 no dac coa reflects analytical data for Modified GRF 1-29, showing a molecular weight of 3367.97 Da. In contrast, a cjc-1295 with dac coa verifies the addition of the Drug Affinity Complex linker, resulting in a higher molecular weight of 3647.28 Da and unique HPLC retention times.
Why is the exact wording cjc 1295 no dac coa critical during vendor evaluation?
Searching specifically for cjc 1295 no dac coa ensures you do not inadvertently purchase CJC-1295 with DAC. Because the DAC modification alters half-life from ~30 minutes to several days, verifying the exact molecular identity on the COA is essential for experimental validity.
What does a high-quality cjc-1295-coa look like?
A valid cjc-1295-coa displays clear raw analytical graphs from RP-HPLC and MS instruments, showing a single sharp peak indicating ≥98% purity, an exact mass match, low endotoxin count (<0.1 EU/mg), and testing accreditation from an independent laboratory.
Why is it important to source a cjc-1295-coa-usa verified batch?
A cjc-1295-coa-usa document confirms that the peptide was analyzed in an accredited US-based analytical facility adhering to ISO 17025 standards, ensuring rigorous quality controls, low heavy metal levels, and accurate reporting.
How do I verify a cjc-1295 coa usa document for authenticity?
Authentic USA certificates list the testing laboratory's contact details, ISO accreditation numbers, clear signatures from quality assurance managers, and matching lot numbers printed on the physical vial.
What mass spectral peak confirms cjc-1295 with dac coa accuracy?
Mass spectrometry for CJC-1295 with DAC must confirm a target monoisotopic mass of 3647.28 Da (often showing ionized m/z peaks representing [M+3H]3+ or [M+4H]4+ states). Any significant variance indicates synthesis errors.
What are the standard endotoxin limits for research-grade CJC-1295?
For high-purity laboratory research, endotoxin levels should measure below 0.1 EU/mg (Endotoxin Units per milligram). Lower endotoxin counts prevent unspecific inflammatory responses in cellular assays and animal models.
How should CJC-1295 be stored upon receipt in the lab?
Lyophilized CJC-1295 should be stored at -20°C upon receipt. After reconstitution in sterile bacteriostatic water, the liquid solution should be kept refrigerated at 2°C to 8°C and used within 30 days, or aliquoted and stored at -80°C to avoid repeated freeze-thaw cycles.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.